CRAPT-M: An effective prognostic predictor for hepatocellular carcinoma patients treated with locoregional-bevacizumab-immunotherapy

Table 5 Multivariate Cox regression analyses of the prognostic factors for overall survival and progression-free survival

Variable	Multivariate Cox regression of OS			Multivariate Cox regression of PFS
	HR	95%CI	P value	HR	95%CI	P value
Tumor size (cm)
0-7
> 7	1.10	0.79-1.53	0.59
Tumor number
Solitary
Multiple	1.59	1.15-2.21	< 0.01	1.41	1.05-1.89	0.02
Child-Pugh
A
B	1.31	0.92-1.88	0.14	1.20	0.86-1.66	0.29
BCLC
A
B				0.98	0.56-1.76	0.94
C				0.99	0.94-1.76	0.98
CRAFITY
0
1	1.03	0.58-1.85	0.92	0.79	0.50-1.25	0.32
2	1.09	0.56-2.15	0.79	0.85	0.49-1.47	0.56
CRAPT-M
Low-risk
Intermediate-risk	1.50	0.82-2.73	0.19	1.10	0.69-1.76	0.68
High-risk	2.52	1.34-4.75	< 0.01	1.87	1.13-3.09	0.01
Extrahepatic metastasis
No
Yes	1.75	1.28-2.41	< 0.01
Transarterial therapies
HAIC
TACE				1.28	0.94-1.76	0.12

OS: Overall survival; PFS: Progression-free survival; BCLC: Barcelona Clinic Liver Cancer; HAIC: Hepatic arterial infusion chemotherapy; TACE: Transarterial chemoembolization.